Keros Therapeutics (NASDAQ:KROS) Sets New 52-Week Low – What’s Next?

Keros Therapeutics, Inc. (NASDAQ:KROS)’s stock price reached a new 52-week low on Tuesday . The company traded as low as $12.35 and last traded at $12.82, with a volume of 2313529 shares changing hands. The stock had previously closed at $14.56.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on KROS shares. Guggenheim downgraded shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday, December 16th. William Blair lowered shares of Keros Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, December 12th. Wells Fargo & Company increased their price target on Keros Therapeutics from $88.00 to $111.00 and gave the stock an “overweight” rating in a report on Wednesday, December 11th. Jefferies Financial Group initiated coverage on Keros Therapeutics in a research report on Tuesday, November 5th. They set a “buy” rating on the stock. Finally, HC Wainwright dropped their price target on Keros Therapeutics from $100.00 to $47.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. Four research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat, Keros Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $75.00.

Keros Therapeutics Trading Down 16.5 %

The business’s 50-day moving average is $39.77 and its two-hundred day moving average is $47.88.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The business had revenue of $0.39 million for the quarter. During the same period last year, the firm earned ($1.33) earnings per share. The company’s revenue was up 4750.0% compared to the same quarter last year. On average, research analysts predict that Keros Therapeutics, Inc. will post -4.74 EPS for the current fiscal year.

Hedge Funds Weigh In On Keros Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. KBC Group NV raised its position in Keros Therapeutics by 52.0% in the third quarter. KBC Group NV now owns 1,263 shares of the company’s stock worth $73,000 after acquiring an additional 432 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Keros Therapeutics by 26.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after purchasing an additional 280 shares during the last quarter. Values First Advisors Inc. bought a new stake in shares of Keros Therapeutics in the 3rd quarter worth approximately $89,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in Keros Therapeutics in the second quarter valued at approximately $128,000. Finally, LMR Partners LLP bought a new position in Keros Therapeutics during the third quarter valued at $213,000. Institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.